vs
Side-by-side financial comparison of Chatham Lodging Trust (CLDT) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
Chatham Lodging Trust is the larger business by last-quarter revenue ($67.5M vs $38.3M, roughly 1.8× ImmunityBio, Inc.). Chatham Lodging Trust runs the higher net margin — 1.1% vs -161.8%, a 162.9% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -1.6%).
Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
CLDT vs IBRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $67.5M | $38.3M |
| Net Profit | $725.0K | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | 2.4% | -169.0% |
| Net Margin | 1.1% | -161.8% |
| Revenue YoY | -1.6% | 407.0% |
| Net Profit YoY | — | -4.7% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $67.5M | — | ||
| Q4 25 | $67.7M | $38.3M | ||
| Q3 25 | $78.4M | $32.1M | ||
| Q2 25 | $80.3M | $26.4M | ||
| Q1 25 | $68.6M | $16.5M | ||
| Q4 24 | $75.1M | $7.6M | ||
| Q3 24 | $87.2M | $6.1M | ||
| Q2 24 | $86.5M | — |
| Q1 26 | $725.0K | — | ||
| Q4 25 | $4.6M | $-61.9M | ||
| Q3 25 | $3.5M | $-67.3M | ||
| Q2 25 | $5.4M | $-92.6M | ||
| Q1 25 | $1.5M | $-129.6M | ||
| Q4 24 | $-1.7M | $-59.2M | ||
| Q3 24 | $4.3M | $-85.7M | ||
| Q2 24 | $6.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | 40.7% | — | ||
| Q3 24 | 44.7% | — | ||
| Q2 24 | 46.1% | — |
| Q1 26 | 2.4% | — | ||
| Q4 25 | 15.9% | -169.0% | ||
| Q3 25 | 12.7% | -173.5% | ||
| Q2 25 | 14.8% | -269.8% | ||
| Q1 25 | 12.1% | -390.1% | ||
| Q4 24 | 7.5% | -919.0% | ||
| Q3 24 | 14.3% | -1314.3% | ||
| Q2 24 | 16.3% | — |
| Q1 26 | 1.1% | — | ||
| Q4 25 | 6.8% | -161.8% | ||
| Q3 25 | 4.5% | -209.8% | ||
| Q2 25 | 6.7% | -350.3% | ||
| Q1 25 | 2.2% | -784.9% | ||
| Q4 24 | -2.3% | -783.4% | ||
| Q3 24 | 4.9% | -1404.0% | ||
| Q2 24 | 7.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | $0.05 | $-0.06 | ||
| Q3 25 | $0.03 | $-0.07 | ||
| Q2 25 | $0.07 | $-0.10 | ||
| Q1 25 | $-0.01 | $-0.15 | ||
| Q4 24 | $-0.08 | $-0.08 | ||
| Q3 24 | $0.05 | $-0.14 | ||
| Q2 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $722.9M | $-500.5M |
| Total Assets | $1.2B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $13.7M | — | ||
| Q4 25 | $24.4M | $242.8M | ||
| Q3 25 | $13.2M | $257.8M | ||
| Q2 25 | $17.2M | $153.7M | ||
| Q1 25 | $18.6M | $61.6M | ||
| Q4 24 | $20.2M | $149.8M | ||
| Q3 24 | $19.3M | $130.4M | ||
| Q2 24 | $10.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | $338.9M | — | ||
| Q3 25 | $338.8M | — | ||
| Q2 25 | $351.2M | — | ||
| Q1 25 | $381.1M | — | ||
| Q4 24 | $406.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $722.9M | — | ||
| Q4 25 | $740.8M | $-500.5M | ||
| Q3 25 | $749.4M | $-524.3M | ||
| Q2 25 | $754.1M | $-570.7M | ||
| Q1 25 | $754.7M | $-591.4M | ||
| Q4 24 | $758.2M | $-489.1M | ||
| Q3 24 | $765.3M | $-745.1M | ||
| Q2 24 | $766.5M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $501.9M | ||
| Q3 25 | $1.2B | $519.0M | ||
| Q2 25 | $1.2B | $402.1M | ||
| Q1 25 | $1.2B | $303.8M | ||
| Q4 24 | $1.3B | $382.9M | ||
| Q3 24 | $1.3B | $364.6M | ||
| Q2 24 | $1.3B | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-70.4M |
| Free Cash FlowOCF − Capex | — | $-71.3M |
| FCF MarginFCF / Revenue | — | -186.2% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $64.1M | $-70.4M | ||
| Q3 25 | $25.6M | $-68.9M | ||
| Q2 25 | $22.1M | $-79.7M | ||
| Q1 25 | $4.2M | $-85.9M | ||
| Q4 24 | $73.8M | $-85.1M | ||
| Q3 24 | $28.8M | $-98.8M | ||
| Q2 24 | $25.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-71.3M | ||
| Q3 25 | — | $-69.6M | ||
| Q2 25 | — | $-80.8M | ||
| Q1 25 | — | $-87.0M | ||
| Q4 24 | — | $-87.3M | ||
| Q3 24 | — | $-101.6M | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -186.2% | ||
| Q3 25 | — | -217.2% | ||
| Q2 25 | — | -305.9% | ||
| Q1 25 | — | -526.9% | ||
| Q4 24 | — | -1155.4% | ||
| Q3 24 | — | -1663.2% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.90× | — | ||
| Q3 25 | 7.24× | — | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 2.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 3.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLDT
| Room | $61.2M | 91% |
| Other | $4.7M | 7% |
| Food and beverage | $1.6M | 2% |
IBRX
Segment breakdown not available.
